HAMBURG, Germany and OXFORD, England, September 22 /PRNewswire-FirstCall/ -- Evotec AG today announced that Joern Aldag, President & CEO, and Dr John Kemp, Chief Research & Development Officer, will present at the UBS Global Life Sciences Conference at 03.00 p.m. EST on Tuesday, 26 September 2006, at Grand Hyatt, New York City.
The company presentation will be webcast live and will be accessible through the Evotec website at www.evotec.com - Investors. A replay will also be available at www.evotec.com - Investors - Webcasts.
About Evotec AG
Evotec is a leader in the discovery and development of novel small molecule drugs. Both through its own discovery programmes and through contract research partnerships, the Company is generating the highest quality research results to its partners in the pharmaceutical and biotechnology industries.
In proprietary projects, Evotec specialises in finding new treatments for diseases of the Central Nervous System. Evotec has two programmes in clinical development: EVT 201, a partial positive allosteric modulator (pPAM) of the GABAA receptor complex for the treatment of insomnia, and EVT 101, a subtype selective NMDA receptor antagonist for the treatment of Alzheimer’s disease and/or neuropathic pain.
In contract research, Evotec has established itself as the partner of choice for pharmaceutical and biotechnology companies worldwide. The Company provides innovative and often integrated solutions from drug target to clinic through an unmatched range of capabilities, including early stage assay development and screening through to medicinal chemistry and drug manufacturing.
In 2005, Evotec has generated sales of EUR 80 million with 600 employees located in Hamburg, Germany and near Oxford and in Glasgow, UK.
www.evotec.com Contact: Evotec AG Anne Hennecke Director, Investor Relations & Corporate Communications Phone: +49-(0)40-560-81-286 anne.hennecke@evotec.com
Evotec AG
CONTACT: Contact: Evotec AG, Anne Hennecke, Director, Investor Relations &Corporate Communications, Phone: +49-(0)40-560-81-286,anne.hennecke@evotec.com
